[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iodine-resistant-thyroid-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iodine-resistant-thyroid-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100564721","early-phase-1-a-dual-targeting-tracer-tate-rgd-for-the-diagnosis-of-sstr--and-rgd--positive-tumors-100564721",false,"NCT06632860","A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors","a Novel Dual-Targeting Molecular Probe TATE-RGD for the Diagnostic Integration of SSTR2 and αvβ3 Positive Tumors","Inclusion Criteria:\n\n* histologically confirmed various cancer patients;\n* 68Ga-TATE-RGD and 18F-FDG PET\u002FCT within a week;\n* signed written consent.\n\nExclusion Criteria:\n\n* known allergy against TATE-RGD;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.","ALL","18 Years","90 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors.",[27,28,29],"Iodine-resistant Thyroid Cancer","Meningioma","NETs","RECRUITING","2025-07-08",{"date":33,"type":34},"2025-07-09","ACTUAL",{"date":36,"type":34},"2024-08-01",{"date":38,"type":21},"2025-12-30",{"name":40,"class":41},"Peking Union Medical College Hospital","OTHER"]